In today’s precision diagnostics of CLL, we need to be able to detect CNVs affecting TP53, i.e., del(17p), and TP53 mutations in routine diagnostics, since these patients should be considered for targeted therapy (Table 1) (87). This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.